Related by context. All words. (Click for frequent words.) 75 pancreatic adenocarcinoma 74 pleural mesothelioma 73 differentiated thyroid 72 carcinoid tumors 71 Chronic lymphocytic leukemia 71 recurrent glioblastoma multiforme 71 nonsmall cell lung cancer 71 Hepatocellular Carcinoma HCC 71 mycosis fungoides 71 recurrent NSCLC 71 metastatic gastric 71 superficial bladder cancer 71 metastatic renal cell carcinoma 70 metastatic bladder 70 gastric cancers 70 colorectal liver metastases 70 urothelial cancer 70 nonmelanoma skin cancers 70 Acute myeloid leukemia 70 renal tumors 70 medically inoperable 69 gastrointestinal stromal tumor 69 GISTs 69 ADPKD 69 AA Amyloidosis 69 Metastatic breast cancer 69 malignant lymphoma 69 trabectedin 69 metastatic malignant melanoma 69 metastatic RCC 69 non squamous NSCLC 69 basal cell carcinoma BCC 69 pancreatic carcinoma 69 metastatic malignant 69 squamous cell lung cancer 69 bronchogenic carcinoma 69 fallopian tube carcinoma 69 peritoneal carcinomatosis 69 malignant neoplasm 69 smoldering myeloma 69 colorectal carcinoma 69 Glioblastoma Multiforme 69 leukemia AML 69 skeletal metastases 69 Surgical resection 68 Velcade bortezomib 68 sorafenib Nexavar 68 malignant lymphomas 68 Pemetrexed 68 cutaneous squamous cell carcinoma 68 relapsed ovarian cancer 68 renal cell carcinomas 68 cholangiocarcinoma 68 biliary cancer 68 Cholangiocarcinoma 68 malignant ascites 68 IV NSCLC 68 chemoresistant 68 clinically localized prostate 68 seminoma 68 resectable 68 neuroendocrine cancers 68 Radical prostatectomy 68 Papillary 68 unresectable 68 neuroendocrine tumors 68 taxane therapy 68 cutaneous melanoma 68 glioblastoma multiforme GBM 68 thymoma 68 paragangliomas 68 prostate cancer PCa 68 Erlotinib 68 metastatic colorectal 68 nonmetastatic 68 carcinoid 68 metastatic renal cell 68 MGUS 68 bladder cancers 68 relapsed leukemia 68 YONDELIS 68 Myelodysplastic Syndrome 68 HNSCC 67 gastric adenocarcinoma 67 HER2 positive cancers 67 Waldenstrom macroglobulinemia 67 hepatocellular carcinoma HCC 67 nodal metastasis 67 EGFR tyrosine kinase inhibitors 67 chemoradiotherapy 67 metastatic GIST 67 invasive candidiasis 67 prostate adenocarcinoma 67 colorectal cancer CRC 67 malignant growths 67 adjuvant radiotherapy 67 Anaplastic 67 metastatic prostate cancer 67 prostate carcinomas 67 Polycythemia vera 67 mucinous 67 stage IIIB 67 Adjuvant chemotherapy 67 NMIBC 67 Myelodysplastic syndrome 67 thalidomide Thalomid 67 advanced hepatocellular carcinoma 67 secondary hyperparathyroidism 67 NSCLC 67 lichen planus 67 mRCC 67 gefitinib Iressa 67 pheochromocytoma 67 grade cervical intraepithelial 67 recurrent ovarian cancer 67 anti angiogenic therapy 67 ximelagatran 67 neoadjuvant therapy 67 metastatic neuroendocrine tumors 67 preoperative chemotherapy 67 HER2 overexpression 67 vWD 67 malignant pleural mesothelioma MPM 67 stage IIIB IV 67 peritoneal cancer 67 CP CPPS 67 nasopharyngeal cancer 67 Gleevec imatinib 67 minimally symptomatic 67 invasive ductal 67 squamous cell carcinoma SCC 67 relapsing remitting MS RRMS 67 cytoreduction 67 Malignant mesothelioma 67 hepatorenal syndrome 67 Gleevec resistant 67 metastatic lung cancer 66 HER2 positive metastatic breast 66 KRAS status 66 papillary renal cell carcinoma 66 urothelial carcinoma 66 AA amyloidosis 66 hepatocellular carcinomas 66 neovascular diseases 66 Renal Cell Carcinoma RCC 66 diffuse gastric 66 hematopoietic cancers 66 renal carcinoma 66 malignant neoplasms 66 allogeneic HSCT 66 Idiopathic Pulmonary Fibrosis 66 Doxil ® 66 pancreatic NET 66 gastrointestinal stromal tumors GIST 66 proliferative diabetic retinopathy 66 stage IIIA 66 oral Hycamtin 66 leiomyomas 66 liver metastasis 66 gastrointestinal stromal tumors 66 lobular carcinoma 66 cytoreductive surgery 66 Vandetanib 66 prostate cancer CRPC 66 soft tissue sarcomas 66 Nilotinib 66 unresectable tumors 66 epithelial tumors 66 hepatocellular cancer 66 locoregional 66 relapsed MM 66 Myelodysplastic Syndrome MDS 66 GIST tumors 66 liver resection 66 Dasatinib 66 hepatic metastases 66 PCa 66 angiosarcoma 66 intravenous bisphosphonates 66 situ CIS 66 pancreatic islet cell 66 ZACTIMA 66 adenomatous 66 Gastric cancer 66 intestinal metaplasia 66 myelodysplastic syndrome MDS 66 bevacizumab Avastin 66 CMV disease 66 axitinib 66 relapsed SCLC 66 metastatic renal 66 PCNSL 66 benign neoplasms 66 KRAS mutation 66 allogeneic stem cell 66 geographic atrophy 66 gastrointestinal stromal tumors GISTs 66 prostate cancer CaP 66 CTEPH 66 biliary tract cancer 66 tigecycline 66 histologic subtype 66 non squamous 66 Hodgkin lymphoma HL 66 Carcinoid tumors 66 hormone refractory 66 mycophenolate mofetil 66 Metastatic 65 carcinoid tumor 65 thyroid nodules 65 ovarian carcinoma 65 endocrine therapies 65 operable breast cancer 65 T1c 65 LHRH agonists 65 Alemtuzumab 65 breast pancreatic 65 VFEND 65 breast carcinoma 65 locoregional recurrence 65 papillary carcinoma 65 endometrial hyperplasia 65 candidemia 65 cervical carcinoma 65 chemotherapy cisplatin 65 precancerous condition 65 tyrosine kinase inhibitors TKIs 65 prostate carcinoma 65 concurrent chemoradiation 65 pegylated liposomal doxorubicin 65 gastric carcinoma 65 erlotinib Tarceva ® 65 Acute Myeloid Leukaemia AML 65 transplantation HCT 65 Degarelix 65 chronic periodontitis 65 basal cell cancers 65 antiangiogenic therapy 65 Anthracycline 65 Amrubicin 65 histologies 65 inoperable pancreatic cancer 65 cisplatin chemotherapy 65 alkylating agent 65 metastatic kidney 65 allogeneic bone marrow 65 Crizotinib 65 HER2 positive breast cancer 65 B Cell Lymphoma 65 metastatic pancreatic 65 sarcomatoid 65 bladder carcinoma 65 myelofibrosis polycythemia vera 65 invasive aspergillosis 65 Nexavar sorafenib 65 mCRC patients 65 Medullary thyroid cancer 65 platinum refractory 65 lung adenocarcinomas 65 Aplidin 65 myeloid leukemia 65 neoadjuvant treatment 65 AAT deficiency 65 serous ovarian cancer 65 Sjögren syndrome 65 calcineurin inhibitors 65 Basal cell 65 recurrent metastatic 65 multiple myeloma MM 65 tuberous sclerosis TS 65 curative therapy 65 SHPT 65 Temsirolimus 65 mesotheliomas 65 ankylosing spondylitis AS 65 bone metastasis 65 TheraSphere 65 interstitial pneumonia 65 gastric cancer 65 Lung transplantation 65 premalignant lesions 65 squamous cell cancer 65 Adenomas 65 colorectal adenocarcinoma 65 gastrointestinal stromal tumor GIST 65 cinacalcet 65 Radiofrequency ablation 65 node metastases 65 Squamous 65 ErbB2 positive 65 Dacogen decitabine 65 follicular lymphomas 65 invasive carcinoma 65 hypertrophic scars 65 medullary thyroid cancer 65 stem cell transplantations 65 K ras mutations 65 Glioblastoma multiforme 65 KRAS mutations occur 65 tumor recurrence 65 PARP inhibition 65 extrapleural pneumonectomy 65 Carcinoma 65 adriamycin 65 Navelbine 65 heavily pretreated 65 gemcitabine chemotherapy 65 cisplatin resistant 65 liver metastases 65 Natalizumab 65 temsirolimus 65 anterior uveitis 65 SIR Spheres 65 PAOD 65 indolent NHL 64 Sezary syndrome 64 common hematologic malignancy 64 metastatic colorectal cancer 64 kidney urologic 64 metastatic liver 64 myeloproliferative diseases 64 EGFR inhibitors 64 neoplastic cells 64 Li Fraumeni Syndrome 64 Glioblastoma Multiforme GBM 64 invasive fungal infection 64 metastatic colon cancer 64 TEMODAL 64 bendamustine 64 anti angiogenic agents 64 stage IIIb IV 64 Chronic Prostatitis 64 Hurthle cell 64 pelvic lymphadenectomy 64 advanced epithelial ovarian 64 elacytarabine 64 chemotherapeutic regimens 64 mTOR inhibitors 64 Multiple Myeloma MM 64 hematological malignancy 64 completely resected 64 cytoreductive nephrectomy 64 plasminogen activators 64 Gefitinib 64 primary hyperparathyroidism 64 depsipeptide 64 acute leukemias 64 infective endocarditis 64 myeloproliferative disorder 64 Adenocarcinoma 64 Aflibercept 64 osteosarcomas 64 neoadjuvant chemotherapy 64 LHRH receptor positive 64 adjuvant therapies 64 paraganglioma 64 taxane chemotherapy 64 localized prostate 64 metachronous 64 Xanafide 64 epithelial ovarian cancer 64 nasopharyngeal carcinoma 64 HER2 positive 64 B CLL 64 curative resection 64 dacarbazine chemotherapy 64 squamous histology 64 BCG refractory 64 ELACYT 64 proliferative retinopathy 64 haematologic malignancies 64 HIV HCV coinfected 64 pancreatic neuroendocrine tumors 64 Vidaza azacitidine 64 advanced NSCLC 64 lymphoid malignancies 64 PNET 64 BR.# 64 trastuzumab Herceptin ® 64 idiopathic pulmonary fibrosis IPF 64 GIST 64 Atypical Hemolytic Uremic Syndrome 64 MGd 64 HER2 positivity 64 Diabetic nephropathy 64 HGPIN 64 CIN2 + 64 SCCHN 64 laryngeal cancer 64 cediranib 64 Endometrial cancer 64 Acute Myelogenous Leukemia AML 64 situ LCIS 64 irinotecan chemotherapy 64 multimodality therapy 64 Taxotere ® 64 Follicular Lymphoma 64 lung adenocarcinoma 64 prophylactic cranial irradiation 64 pT2 64 pancreatectomy 64 myeloproliferative neoplasms 64 Adjuvant therapy 64 alveolar rhabdomyosarcoma 64 Myelofibrosis 64 SSc 64 HBeAg negative 64 postoperative chemotherapy 64 allogeneic hematopoietic stem cell 64 efalizumab 64 breast carcinomas 64 GW# [003] 64 Candida infection 64 pulmonary hypertension PH 64 Mitoxantrone 64 pediatric malignancies 64 Chronic Lymphocytic Leukemia 64 Sentinel node biopsy 64 gemcitabine Gemzar 64 Leukemias 64 hypervascular tumors 64 Bevacizumab 64 CYT# potent vascular disrupting 63 histological subtype 63 benign prostatic hypertrophy BPH 63 hematologic disorders 63 myeloproliferative disorders 63 extracranial 63 Gleevec imatinib mesylate 63 malignant mesothelioma 63 Cloretazine 63 BRAF inhibitor 63 Glioma 63 thymic carcinoma 63 PsA 63 histologically confirmed 63 EGFR mutation positive 63 metastatic bone 63 acute promyelocytic leukemia 63 chlorambucil 63 ovarian breast 63 chronic lymphocytic leukemia CLL 63 alemtuzumab treated 63 epithelial ovarian 63 transthyretin amyloidosis 63 tumors GIST 63 recurrent colorectal cancer 63 somatostatin analogues 63 histopathologic examination 63 refractory acute myeloid 63 T1a 63 portal vein thrombosis 63 hepatocellular carcinoma 63 Pertuzumab 63 INCB# [003] 63 Pulmonary Arterial Hypertension PAH 63 percutaneous biopsy 63 pilocytic astrocytomas 63 Malignant Melanoma 63 Chronic Myeloid Leukemia CML 63 cervical lymph nodes 63 refractory AML 63 oropharyngeal candidiasis 63 Torisel 63 Meningiomas 63 erlotinib Tarceva 63 bladder tumors 63 surgically resectable 63 acute myeloid 63 metastatic adenocarcinoma 63 advanced unresectable 63 pituitary adenomas 63 refractory ovarian cancer 63 Retreatment 63 Irinotecan 63 Myelodysplastic syndromes MDS 63 neoplasm 63 lupus nephritis 63 Tyrosine Kinase Inhibitors 63 metastatic cancer 63 CIMZIA ™ 63 lymphoma subtypes 63 metastatic lesions 63 adjuvant radiation 63 biochemical recurrence 63 indolent lymphomas 63 adverse cytogenetics 63 haematologic 63 gastrointestinal cancers 63 Glioblastoma 63 primary immunodeficiency PI 63 sleeve lobectomy 63 KRAS wild 63 ductal breast cancer 63 intravesical therapy 63 Glivec imatinib 63 Mantle Cell Lymphoma 63 advanced adenomas 63 Mitomycin C 63 thoracoscopic lobectomy 63 Critical Limb Ischemia CLI 63 metastatic carcinoma 63 refractory colorectal cancer 63 OPAXIO 63 NovoTTF 63 neuroendocrine carcinoma 63 subependymal giant cell 63 Sjogren Syndrome 63 MAGE A3 ASCI 63 Bronchiectasis 63 distant metastasis 63 cetuximab Erbitux 63 chemoembolization 63 CYPHER Stent 63 haematological cancers 63 Paraplatin ® 63 imatinib resistance 63 HCV infections 63 tipranavir ritonavir 63 atrophic gastritis 63 Gliadel Wafer 63 Idiopathic pulmonary fibrosis 63 prospective multicenter study 63 Zarnestra 63 cardiotoxic 63 cystectomy 63 chronic GVHD 63 BEXXAR Therapeutic Regimen 63 enzastaurin 63 basal cell skin 63 neovascular 63 basal cell nevus syndrome 63 ductal adenocarcinoma 63 BRAF V#E mutation 63 imatinib Gleevec 63 biliary tract cancers 63 juvenile idiopathic arthritis JIA 63 riociguat 63 vinca alkaloids 63 Liver transplantation 63 Genasense ® 63 relapsed ALL 63 recurrent GBM 63 Aortic stenosis 63 LV dysfunction 63 nonmelanoma skin cancer 63 gefitinib 63 GnRH agonists 63 Zolinza 63 cancer mCRC 63 Relapsing remitting MS 63 biologic therapy 63 follicular thyroid cancer 63 sentinel lymph node biopsy 63 Cardiotoxicity 63 resected pancreatic cancer 63 Venous thromboembolism 63 recurrent glioblastoma 63 invasive lobular 63 Chronic Lymphocytic Leukemia CLL 63 oligodendrogliomas 63 Haptoglobin 63 Hepatocellular Carcinoma 63 acne vulgaris 63 Epratuzumab 63 TKI therapy 63 unresectable stage 63 ductal carcinomas 63 Enzastaurin 63 T#I [002] 63 Toxicities 63 Prostatitis 63 total thyroidectomy 63 mutated KRAS 63 infective endocarditis IE 63 Chronic HCV 63 EUS FNA 63 carcinoma HCC 63 rFVIIa 63 adrenocortical cancer 63 DOXIL 63 Chronic pancreatitis 63 Nephrogenic Systemic Fibrosis NSF 63 Soft Tissue Sarcoma 63 metastatic castration resistant 63 IMA# 63 adult chronic ITP 63 Hematologic 63 underwent surgical resection 63 Langerhans cell histiocytosis 63 myelodysplastic myeloproliferative diseases 63 Hycamtin 63 symptomatic BPH 63 brain metastases 63 Alequel 63 olaparib 63 oral clodronate 63 anthracycline taxane 63 neoplasias 62 MELAS 62 advanced adenoma 62 Lenalidomide 62 MALT lymphoma 62 GBM tumors 62 androgen ablation 62 testicular cancers 62 pan HDAC inhibitor 62 metastatic carcinoid tumors 62 metastatic melanoma 62 FluCAM arm 62 follicular lymphoma FL 62 metastatic hormone refractory 62 sunitinib Sutent 62 PROLARIS 62 hematological diseases 62 ZACTIMA TM ZD# 62 nonalcoholic steatohepatitis NASH 62 Naive Patients 62 radiochemotherapy 62 anticancer therapy 62 non resectable 62 Roche Xeloda 62 pouchitis 62 FDG PET imaging 62 vinca alkaloid 62 acute coronary syndromes ACS 62 Aspergillus infections 62 prostate cancer HRPC 62 castrate resistant prostate cancer 62 elevated LDH 62 Selective Internal 62 oesophageal adenocarcinoma 62 Epstein Barr virus EBV 62 Metastatic melanoma 62 thrombotic complications 62 anaplastic 62 LVNC 62 grade gliomas 62 androgen deprivation 62 cutaneous lupus 62 precursor lesions 62 clinicopathological 62 chronic granulomatous disease 62 dasatinib Sprycel 62 pancreatic lung 62 Onrigin 62 renal cell carcinoma 62 esophagogastric junction 62 intestinal polyps 62 palliative radiotherapy 62 aromatase inhibitors AIs 62 Cytoxan 62 orchitis 62 underwent resection 62 pulmonary metastases 62 histone deacetylase HDAC inhibitor 62 esophageal gastric 62 Squamous Cell Carcinoma 62 colorectal neoplasms 62 systemic scleroderma 62 lymphocytic leukemia 62 lung tumors 62 SJIA 62 Fludara ® 62 idiopathic myelofibrosis 62 Unresectable 62 Gemzar ® 62 Malignant glioma 62 imatinib Gleevec ® 62 epithelioid 62 leiomyoma 62 Telatinib 62 chemoradiation therapy 62 Barrett esophagus 62 Pleural mesothelioma 62 familial adenomatous polyposis 62 breast endometrial 62 dermatofibrosarcoma protuberans 62 radiosensitive 62 pancreatic prostate 62 docetaxel Taxotere ® 62 Cetuximab 62 acute leukemia AML 62 alkylating agents 62 recurrent glioblastoma multiforme GBM 62 immunocompetent 62 STRIDE PD 62 Tarceva erlotinib 62 HeFH 62 Surgical excision 62 metastatic ovarian cancer 62 Glioblastoma multiforme GBM 62 Sorafenib 62 advanced metastatic renal 62 intensive statin therapy 62 Navelbine ® 62 recurrent prostate cancer 62 Neoplasms 62 vorinostat 62 choriocarcinoma 62 Epithelial ovarian cancer 62 Stage IIIb 62 Wegener granulomatosis 62 pain palliation 62 lymphoproliferative disorders 62 grade serous ovarian 62 ischemic cardiomyopathy 62 OncoVEX GM CSF 62 hepatectomy 62 sunitinib malate 62 leukemia ALL 62 Prognostic factors 62 erythema nodosum 62 stratifying patients 62 external beam radiotherapy 62 immune thrombocytopenic purpura 62 vinorelbine 62 HNPCC 62 Epidermal Growth Factor Receptor 62 adenocarcinomas 62 basiliximab 62 HRPC 62 Cystectomy 62 carcinoma 62 Advanced Renal Cell 62 intra abdominal abscess 62 immunosuppressive therapies 62 ATTR CM 62 standard chemotherapy regimen 62 non hodgkin lymphoma 62 pT3 62 TACE 62 glomerulonephritis 62 Interferon alfa 62 tumor histology 62 squamous cell cancers 62 Occlusive Disease 62 bullous 62 PROCHYMAL 62 micrometastases 62 leukemia CLL 62 liposomal doxorubicin 62 virotherapy 62 lung metastases 62 cabazitaxel 62 Eisenmenger syndrome 62 Gliomas 62 MabCampath 62 mutated K ras 62 cerebral vasospasm 62 bevacizumab Avastin ® 62 ruboxistaurin 62 sinonasal 62 radiofrequency ablation RFA 62 non resectable metastatic 62 choroidal neovascularization 62 MYCN amplification 62 malignant lesions 62 patientswith 62 pneumonectomy 62 thoracic aortic aneurysms 62 alpha interferons 62 adenomatous polyps 62 Avastin bevacizumab 62 superficial basal cell carcinoma 62 hypereosinophilic syndrome 62 Non Hodgkins lymphoma 62 relapsing multiple sclerosis 62 Ankylosing spondylitis 62 paclitaxel Taxol R 62 undergone radical prostatectomy 62 Severe Primary IGFD 62 EndoTAGTM 1 62 bladder ovarian 62 Ceplene/IL-2 62 noninfectious uveitis 62 iniparib BSI 62 primitive neuroectodermal tumor 62 TTF Therapy 62 chronic pancreatitis 62 castration resistant prostate cancer 62 endocrine tumors 62 CTAP# Capsules 62 thyrotoxicosis 62 gastroesophageal junction 62 esophagectomy 62 nonalcoholic steatohepatitis 62 EGFR mutation 62 advanced metastatic prostate 62 refractory CLL 62 HQK 62 TORISEL 62 pemphigus 62 angiographically 62 posaconazole 62 bleomycin 62 AVOREN 62 atypical hemolytic uremic syndrome 62 efaproxiral 62 Olaparib 62 FOLFIRINOX 62 thrombocytopenic 62 lymph node dissection 62 chronic idiopathic thrombocytopenic purpura 62 debulking surgery 62 Philadelphia Chromosome Positive 62 Bleomycin 62 cytotoxic therapy 62 papillary thyroid carcinoma 62 doublet chemotherapy 62 p# biomarker 62 XELOX 62 smoldering multiple myeloma 62 lymphadenectomy 62 tumor necrosis 62 panitumumab Vectibix 62 receptor tyrosine kinase inhibitor 62 nonmelanoma 62 colorectal lung 62 bortezomib Velcade 62 Imiquimod 62 Trabectedin 62 Campath alemtuzumab 62 proliferative disorders 62 prognostic variables 62 demonstrated antitumor activity 62 anthracycline chemotherapy 62 relapsed refractory multiple myeloma 62 relapsed GBM 62 Chronic sinusitis 62 hamartomas 62 antimetabolite 62 immunohistochemical staining 62 EGFR TKI 62 chronic HBV infection 62 leukemias lymphomas 62 metastatic cancers 62 Arranon 62 Fluorouracil 62 percutaneous cryoablation 62 valvular heart 62 Neoadjuvant 62 acute lymphoblastic 62 resistant hormone refractory 61 cirrhosis liver failure 61 azacytidine 61 FDG-PET/CT 61 endoscopic ultrasonography 61 histologic diagnosis 61 radical nephrectomy 61 castrate resistant 61 FOLFOX4 61 squamous 61 sorafenib tablets 61 psoriatic arthritis PsA 61 nodal metastases 61 lymphomas leukemias 61 antiproliferative effects 61 thromboembolic disease 61 metaplasia 61 PTLD 61 cranial irradiation 61 AEG# 61 thromboembolic events 61 cytotoxic chemotherapy 61 teriflunomide 61 hormone receptor negative 61 acute aortic dissection 61 decompensated cirrhosis 61 Metastatic colorectal cancer 61 ductal cancer 61 oropharyngeal cancer 61 SUTENT 61 diabetic kidney 61 taxane refractory 61 Sudhir Agrawal D.Phil 61 postoperative morbidity 61 CIN3 61 5FU 61 allogeneic transplant 61 metastatic basal cell 61 terlipressin 61 tafamidis 61 mutated KRAS gene 61 Lymph node 61 radical cystectomy 61 transarterial 61 Rituxan rituximab 61 essential thrombocythemia ET 61 invasive fungal infections 61 Endoscopic ultrasound 61 Halaven 61 VaD 61 percutaneous vertebroplasty 61 liposomal amphotericin B 61 vandetanib 61 metastatic CRC 61 Tavocept 61 angiogenesis inhibition 61 neoplasms 61 immunosuppressive regimens 61 recurrent glioma 61 neoadjuvant setting 61 recurrent DVT 61 Morquio 61 docetaxel Taxotere 61 antiangiogenic agent 61 astrocytomas 61 precancerous cervical lesions 61 relapsed CLL 61 squamous cell histology 61 ZOLINZA 61 juvenile myelomonocytic leukemia 61 Androgen deprivation therapy 61 metastatic 61 Rectal cancer 61 MPGN 61 heavily pretreated patients 61 Sanofi Aventis Taxotere 61 MYLOTARG 61 immunomodulatory therapy 61 cardiac allograft vasculopathy 61 EGFR blockers 61 lenalidomide Revlimid R 61 Hodgkin lymphoma NHL 61 paroxysmal nocturnal hemoglobinuria 61 Carboplatin 61 Renal cell carcinoma 61 microsatellite instability 61 malignant fibrous histiocytoma 61 chronic HBV 61 trans retinoic acid 61 Tesmilifene 61 sunitinib 61 cell carcinoma 61 HER2 receptor 61 autoimmune hemolytic anemia 61 Trastuzumab 61 polycythemia vera PV 61 familial ALS 61 invasive lobular carcinoma 61 pheochromocytomas 61 Xelox 61 esophageal cancers 61 Estrogen Receptor 61 polyp recurrence 61 Intravenous immunoglobulin 61 malignant pheochromocytoma 61 Gorlin syndrome 61 ELOXATIN 61 transurethral resection 61 Systemic Lupus Erythematosus SLE 61 Fludarabine 61 transplantation HSCT 61 noncancer 61 neoplastic 61 IFN beta 61 Aviptadil 61 hyperparathyroidism 61 cortical dysplasia 61 temozolomide Temodar 61 Fludara 61 Non Hodgkin 61 NOMID 61 myeloablative 61 Xeloda capecitabine 61 null responder 61 antitumor effect 61 doxorubicin Adriamycin 61 trastuzumab Herceptin 61 eflornithine 61 localized renal 61 pediatric acute lymphoblastic 61 metastatic pancreatic cancer 61 interstitial cystitis IC 61 Paraplatin ® carboplatin 61 Aprotinin 61 ALND 61 atherothrombosis 61 Vectibix monotherapy 61 Liprotamase 61 retrospective cohort 61 Taxol ® 61 untreated celiac disease 61 deferiprone 61 Chronic Myelogenous Leukemia 61 alpha1 antitrypsin deficiency 61 nephron sparing surgery 61 IDH1 mutation 61 anemias 61 Anthracyclines 61 idiopathic pulmonary 61 complement inhibitor eculizumab 61 carcinoids 61 Myelodysplastic Syndromes 61 dasatinib Sprycel ® 61 eosinophilic pneumonia 61 Neulasta ® 61 Renal Cell Carcinoma